Kate Therapeutics is a patient-centric biotechnology company developing adeno-associated virus (AAV)-based gene therapies for genetically defined muscle and heart diseases. Its technology platforms aim to address major limitations of current gene therapies, including tissue-specific delivery and gene regulation, with the potential to improve efficacy and safety. The company intends to advance an initial internal portfolio of muscle and heart disease programs, including myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD). It will use newly raised funds to support progression of these programs. The company is led by president and CEO Kevin Forrest, Ph.D. Kate Therapeutics is based in San Diego, CA.

Total raised

$51M

Funding rounds

1

Latest round

Series A

Latest activity

Jun 2023